Streetbeat News

Price Targets

CYBR

JMP Securities analyst Trevor Walsh has reiterated a 'Market Outperform' rating on CyberArk Software (NASDAQ:CYBR) and maintained a price target of $195.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 1:04 pm

CRWD

JMP Securities analyst Trevor Walsh has reiterated a Market Outperform rating on CrowdStrike Holdings (NASDAQ:CRWD) and maintained a $235 price target.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 1:03 pm

KMPR

JMP Securities analyst Matthew Carletti maintains a Market Outperform rating on Kemper (NYSE:KMPR) but lowers the price target from $85 to $75.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 1:01 pm

ARE

Wedbush analyst Richard Anderson has reiterated an Outperform rating on Alexandria Real Estate (NYSE:ARE) and maintained a $120 price target.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:52 pm

CATY

Wedbush analyst David Chiaverini maintains an Outperform rating on Cathay General (NASDAQ:CATY) but lowers the price target from $42 to $40.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:50 pm

HOPE

Wedbush analyst David Chiaverini has maintained a Neutral rating on Hope Bancorp (NASDAQ:HOPE) and lowered the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:42 pm

WEX

Morgan Stanley analyst James Faucette has maintained an Equal-Weight rating on WEX (NYSE:WEX) and raised the price target from $200 to $205.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:39 pm

WIX

Seaport Global analyst Aaron Kessler has initiated coverage on Wix.com (NASDAQ:WIX) with a Buy rating and a price target of $103.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:37 pm

TMO

Morgan Stanley analyst Tejas Savant has maintained an Overweight rating on Thermo Fisher Scientific (NYSE:TMO) but lowered the price target from $640 to $600.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:35 pm

PACB

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Pacific Biosciences (NASDAQ:PACB) and lowered the price target from $13 to $10.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:34 pm